Homocysteine-Lowering Therapy and Risk of Recurrent Stroke, Myocardial Infarction and Death: The Impact of Age in the VISP Trial

Publisher： Karger

E-ISSN： 1421-9786|37|4|263-267

ISSN： 1015-9770

Source： Cerebrovascular Diseases, Vol.37, Iss.4, 2014-04, pp. : 263-267

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The VITATOPS (Vitamins to Prevent Stroke) Trial: Rationale and Design of an International, Large, Simple, Randomised Trial of Homocysteine-Lowering Multivitamin Therapy in Patients with Recent Transient Ischaemic Attack or Stroke

By  

Cerebrovascular Diseases, Vol. 13, Iss. 2, 2002-02 ,pp. : 120-126

Karger

Access to resources Recommend Favorite

Homocysteine and hemostatic disorder as a risk factor for myocardial infarction at a young age

By Ogawa M.   Abe S.   Saigo M.   Biro S.   Toda H.   Matsuoka T.   Torii H.   Minagoe S.   Maruyama I.   Tei C.  

Thrombosis Research, Vol. 109, Iss. 5, 2003-03 ,pp. : 253-258

Elsevier

Access to resources Recommend Favorite

Sustained Homocysteine-Lowering Effect over Time of Folic Acid-Based Multivitamin Therapy in Stroke Patients despite Increasing Folate Status in the Population

By  

Cerebrovascular Diseases, Vol. 19, Iss. 2, 2005-02 ,pp. : 110-116

Karger

Access to resources Recommend Favorite

Recurrent myocardial infarction associated with gefitinib therapy

By Lynch Donald  

Journal of Thrombosis and Thrombolysis, Vol. 32, Iss. 1, 2011-07 ,pp. : 120-124

Springer Publishing Company

Access to resources Recommend Favorite

Demographic and Technical Risk Factors of 30-Day Stroke, Myocardial Infarction, and/or Death in Standard- and High-Risk Patients Who Underwent Carotid Angioplasty and Stenting

By  

Interventional Neurology, Vol. 3, Iss. 3-4, 2015-06 ,pp. : 165-173

Karger

Access to resources Recommend Favorite